Advancing the Future of Long Non-Coding RNA (lncRNA) Medicine
Developing first-in-class therapies to precisely target disease-driving long non-coding RNAs (lncRNAs) in oncology and beyond
SCIENCE
lncRNAs: A Vast and Largely Untapped Therapeutic Landscape
Traditional drug development has focused on the ~2% of the genome encoding proteins, leaving ~98% — largely non-coding RNAs, including lncRNAs.
Predominantly uncharacterised, yet a handful of lncRNAs linked to major human diseases.
No approved drugs target lncRNAs — the opportunity to create next frontier first-in-class lncRNA medicine.
APPROACH
Turning lncRNA Biology into Precision Medicines
We employ systematic strategies and integrated proprietary platforms to discover, prioritise, and functionally characterise disease-relevant lncRNAs, and to target them with precision and effectiveness.
AMRQ-ARCANA
01
An advanced computational engine that discovers and prioritises disease-relevant lncRNAs.
AMRQ TARGET ID ATLAS
02
A curated atlas of functionally validated and high-confidence disease-relevant lncRNA targets.
AMRQ Drug Discovery (DD)
03
A dedicated drug discovery and development program focused on creating effective therapies that target pathogenic lncRNAs.
Amaroq is Focused on High-Quality Programs for Oncology First
Oncology programs are prioritised based on high unmet need with best-in-class potential geared towards reliable delivery to specific organs, tissues and cells of interest.
PIPELINE
ONCOLOGY
Undisclosed Target 1
ONCOLOGY
Undisclosed Target 2
Core Team Members
Core Team Members
Board of Directors
Board of Directors
Our partners
& investors
Our partners & investors
